Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs
Latigo Biotherapeutics will apply the IPO proceeds toward a pipeline that includes a next-generation non-opioid…
Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs
Latigo Biotherapeutics will apply the IPO proceeds toward a pipeline that includes a next-generation non-opioid pain drug ready for pivotal testing. BlossomHill Therapeutics also debuted on the Nasdaq, raising cash for cancer drugs designed to address mutations not covered by currently available therapies. The post Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain…
Why Kidney Care’s Biggest Investment Wave Hasn’t Moved Hospital Costs
The problem may not be the investment. It may be the target of the intervention. The post Why Kidney Care’s Biggest Investment Wave Hasn’t Moved Hospital Costs appeared first on MedCity News.
My Wish For Better Care For Americans Living in Rural Areas
A letter to Medicaid Directors, State Leaders, and other invested collaborators who were awarded Rural Health Transformation (RHT) Grant funding. The post My Wish For Better Care For Americans Living in Rural Areas appeared first on MedCity News.
Journalists Cover Cyclospora and Measles Outbreaks, and Changing Health Policies
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed the cyclosporiasis outbreak on CBS News’ CBS Mornings on Aug. 5. Gounder discussed New Mexico’s measles outbreak on CBS News 24/7’s The Daily Report on Aug. 4. She also discussed peptides on Ideastream Public Media/WKSU’s Sound of Ideas on Aug. 3. Click here to watch…
Bipartisan Lawmakers Are Fighting HHS’ 340B Rebate Push
A bipartisan group of six senators introduced a bill to reform the 340B drug program, locking in hospitals’ use of contract pharmacies and adding new transparency and compliance rules. The legislation would also kill HHS’ contested rebate pilot within a year and replace it with a national data clearinghouse to catch duplicate discounts. The post…
Recovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA
Replimune went from an FDA rejection to a resubmission, a positive advisory committee vote, and finally an accelerated regulatory approval for advanced melanoma — all in less than four months. The FDA nod for Replimune’s oncolytic viral therapy, Tudriqev, positions it as a more convenient alternative to an Iovance Biotherapeutics cell therapy that had been…
Democratic Senators Urge Withdrawal of Interim Final Rule on Medicaid Work Requirements
Democratic senators are urging CMS to withdraw its Medicaid work requirements rule, arguing it will create administrative burdens and cause eligible beneficiaries to lose coverage. The post Democratic Senators Urge Withdrawal of Interim Final Rule on Medicaid Work Requirements appeared first on MedCity News.
HCA Buys Texas Urgent-Care Venture
The deal grows the Nashville-based company’s national network of clinics by more than 10%.
Clinical Research Has a Workforce Problem
Workforce shortages and manual processes are slowing trial enrollment, but technology can help health systems work smarter while keeping people at the center.
The Missing Piece of Preventive Dental Care Lies in the Bite
Historically, prevention has focused on protecting teeth from decay and gum disease. However, long-term oral health is also shaped by how the teeth, muscles, and jaw function together over time. The post The Missing Piece of Preventive Dental Care Lies in the Bite appeared first on MedCity News.
